Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

KDventures

0.24 SEK

+2.13 %

Less than 1K followers

KDV B

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.13 %
-14.89 %
-32.39 %
-21.39 %
-68.81 %
-70.49 %
-84.07 %
-79.19 %
-99.17 %

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

Read more
Market cap
158.29M SEK
Turnover
562.94K SEK
Revenue
1.67M
EBIT %
-11,617.24 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30/4
2026

Interim report Q1'26

12/5
2026

General meeting '26

28/8
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Press release3/11/2026, 9:10 AM

KDventures portföljbolag AnaCardio utökar patentskyddet för AC01 till 2040-talet med nytt USA-patent

KDventures
Press release3/11/2026, 9:10 AM

KDventures’ portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval

KDventures
Press release3/3/2026, 9:49 AM

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS

KDventures

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/3/2026, 9:49 AM

KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS

KDventures
Regulatory press release3/2/2026, 9:22 AM

Finansinspektionen: Flaggningsmeddelande i KDventures AB

KDventures
Regulatory press release3/2/2026, 7:43 AM

Finansinspektionen: Flaggningsmeddelande i KDventures AB

KDventures
Regulatory press release2/27/2026, 7:00 AM

Ändring av antal aktier och röster i KDventures AB

KDventures
Regulatory press release2/27/2026, 7:00 AM

Change of number of shares and votes in KDventures AB

KDventures
Press release2/24/2026, 3:41 PM

KDventures’s portfolio company SVF Vaccines announces that the intended merger with Novakand will not be carried out following negative decision from Nasdaq

KDventures
Press release2/24/2026, 3:41 PM

KDventures portföljbolag SVF Vaccines meddelar att den tilltänkta sammanslagningen med Novakand inte genomförs efter negativt besked från Nasdaq

KDventures
Press release2/16/2026, 4:24 PM

DNB Carnegie Access: KDventures: Approaching decisive data – Q4 review

KDventures
Regulatory press release2/16/2026, 10:48 AM

Finansinspektionen: Flaggningsmeddelande i KDventures AB

KDventures
Regulatory press release2/13/2026, 7:00 AM

Bokslutskommuniké för januari – december 2025

KDventures
Regulatory press release2/13/2026, 7:00 AM

Year-end Report - January-December 2025

KDventures
Regulatory press release2/12/2026, 2:45 PM

KDventures AB (publ) genomför riktad nyemission av aktier till garanter i samband med den genomförda företrädesemissionen

KDventures
Regulatory press release2/12/2026, 2:45 PM

KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue

KDventures
Press release2/10/2026, 12:41 PM

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer

KDventures
Press release2/10/2026, 12:41 PM

KDventures portföljbolag SVF Vaccines utser Raheleh Nassaji till verkställande direktör

KDventures
Press release2/6/2026, 7:05 AM

Karolinska Development’s portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement

KDventures
Press release2/6/2026, 7:05 AM

Karolinska Developments portföljbolag SVF Vaccines ingår avtal med Novakand Pharma om omvänt förvärv

KDventures
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.